Who is sponsoring NCT03495206?

NCT03495206 is sponsored by Yantai YenePharma Co., Ltd..

What drugs are being tested in NCT03495206?

Interventions in NCT03495206: Y-2(Edaravone And Borneol) Sublingual Tablet.

What condition does NCT03495206 study?

NCT03495206 studies Stroke, Acute, Intracranial Hemorrhages.

Is NCT03495206 still recruiting?

NCT03495206 is currently status unknown. Last updated 13 February 2020.

Last reviewed 2020-02-13 · How we verify

NCT03495206

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sublingual Y-2(Edaravone And Borneol) Tablet For Acute Ischemic And Hemorrhagic Patients-the SALVAGE Trial

Status unknown Phase 1 Last updated 13 February 2020

What this trial tests

Phase 1 trial testing Y-2(Edaravone And Borneol) Sublingual Tablet in Stroke, Acute in 24 participants. Status unknown.

Timeline

25 October 2018

Primary endpoint
1 December 2020

1 February 2021

Quick facts

Lead sponsor	Yantai YenePharma Co., Ltd.
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	24
Start date	25 October 2018
Primary completion	1 December 2020
Estimated completion	1 February 2021
Sites	1 location across United States

Drugs / interventions tested

Y-2(Edaravone And Borneol) Sublingual Tablet — full drug profile →

Conditions studied

Stroke, Acute — all drugs for Stroke, Acute →
Intracranial Hemorrhages — all drugs for Intracranial Hemorrhages →

Sponsor

Yantai YenePharma Co., Ltd. — full company profile →

Who can join

Adults 18 to 55, any sex, with Stroke, Acute or Intracranial Hemorrhages. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Number of participants who experience treatment-related adverse events (AEs) and serious adverse events (SAEs)
Time frame: 0 hours to 36 hours
Any untoward medical events during this study were categorized as severe, moderate, or mild, and related or not related to study treatment

Sponsor's own description

The primary objective is to evaluate the safety and tolerability of single ascending dose of Y-2 sublingual tablets in healthy male and female adult subjects. The secondary objective is to characterize the single-dose pharmacokinetics of Y-2 sublingual tablets in healthy male and female adult subjects.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Neuroprotective Phytochemicals in Experimental Ischemic Stroke: Mechanisms and Potential Clinical Applications.
Xu H, Wang E, Chen F, Xiao J, et al · · 2021 · cited 75× · PMID 34007405 · DOI 10.1155/2021/6687386
A Review on Natural Antioxidants for Their Role in the Treatment of Parkinson's Disease.
Mittal P, Dhankhar S, Chauhan S, Garg N, et al · · 2023 · cited 40× · PMID 37513820 · DOI 10.3390/ph16070908
Edaravone Dexborneol mitigates pathology in animal and cell culture models of Alzheimer's disease by inhibiting neuroinflammation and neuronal necroptosis.
Xu C, Mei Y, Yang R, Luo Q, et al · · 2024 · cited 8× · PMID 38678262 · DOI 10.1186/s13578-024-01230-8

Verify or expand the search:

Other recruiting trials for Stroke, Acute

Currently open trials in the same condition.

NCT06825897 — Delay AvoIding Primary Evaluation for ThRombectomy of Acute StrokE Patients With Large Vessel OCclusion in the Angiograp · NA · recruiting
NCT06658197 — Efficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion Stroke · Phase 3 · recruiting
NCT07253870 — Comperative Effects of Transcutaneous Auricular and Cervical Vagus Nerve Stimulation in Subacute Stroke Patients · NA · recruiting
NCT06941753 — Off-script Diagnosis & Differential Diagnosis (D&D) Training and Residents' Stroke Knowledge · NA · recruiting
NCT06123650 — Post Stroke Dysphagia: Effect of Adding rTMS to Conventional Therapy on the Prevalence of Pneumonia. · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03495206 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yantai YenePharma Co., Ltd.
Last refreshed: 13 February 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03495206.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing